ARS Pharmaceuticals, Inc. (SPRY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.65-13.11%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SPRY
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Targeted commercial execution. ARS Pharma is shifting its focus from broad consumer-directed marketing to targeted engagement with high-volume prescribers, a strategy that has already demonstrated to…
Stated in 2 of 2 supplied quarters. Management reported: “neffy U.S. commercial metrics as of the end of the second quarter of 2026 include: • U.S. net product revenue of $26.2 million , bringing 2026 year-to-date net product revenue to $43.7 million; • Total U.S. epinephrine market share of 5% , a doubling of the 2.5% total market share in the same period in 2025; • Market share of 8% among field-targeted accounts compared with 4% share in the same period of 2025; and • Over 16,000 unique prescribers in the second quarter, a nearly threefold increase over the same period in 2025.” Revenue was $33.658 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Targeted commercial execution. ARS Pharma is shifting its focus from broad consumer-directed marketing to targeted engagement with high-volume prescribers, a strategy that has already demonstrated to…”
“• Sales force expansion: ARS Pharma completed the previously announced expansion of its sales force from 106 to 148 representatives and area sales managers, increasing call frequency and depth of eng…”
ARS Pharma has implemented a rigorous cost optimization framework, significantly reducing its SG&A expense, that focuses on building a profitable neffy franchise to drive shareholder value and provid…
Stated in 2 of 2 supplied quarters. Management reported: “As a result, total cash-based SG&A and R&D expenses for the second half of 2026 are expected to be in the range of $100 million to $110 million, driven by a more than 40% reduction in SG&A cash-based expenses from the first half of 2026, with a favorable trend planned to continue through full-year 2027.” “• Path to cash flow breakeven : Based on its revised cash-based expense plan, ARS Pharma anticipates a path to reaching cash flow breakeven by the end of 2027.”
“ARS Pharma has implemented a rigorous cost optimization framework, significantly reducing its SG&A expense, that focuses on building a profitable neffy franchise to drive shareholder value and provid…”
“ARS Pharma believes this cash position is sufficient to fund operations through cash-flow break-even.”
ARS Pharma is extending its intranasal epinephrine platform into CSU.
Stated in 2 of 2 supplied quarters. Management reported: “Given the time required for patients to complete all three episodes for data collection and reporting, ARS Pharma expects interim Phase 2b data in the first quarter of 2027.” “The interim analysis population is fully enrolled, with interim data anticipated in the fourth quarter of 2026, followed by the potential initiation of a single Phase 3 pivotal efficacy study in mid-2027.”
“ARS Pharma is extending its intranasal epinephrine platform into CSU.”
“Clinical Advancement of Intranasal Epinephrine Program • Phase 2b trial in chronic spontaneous urticaria (CSU) on track: ARS Pharma’s Phase 2b trial (NCT06927999) evaluating its intranasal epinephrin…”
Focus on provider adoption and targeted engagement with high-volume prescribers to grow neffy market share and revenue.
Progress Phase 2b trial for chronic spontaneous urticaria (CSU) with interim data expected in Q1 2027 to expand intranasal epinephrine platform.
Over the trailing year it converted 0.98x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.